NTRB Stock Forecast: Nutriband, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.92
−1.60% on the day

The median 12-month analyst price target for Nutriband, Inc. is $15. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 33 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$60.8M
Ticker Nerd rank
33/ 100
Median analyst target
$15
Analysts covering
1
Revenue$438K−29.7% y/y
Operating income−$891K
Net income−$881K
Free cash flow−$585K
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.3%
1M
−15.9%
YTD
+8.4%
1Y
−2.4%
From 52W high
−45.3%
From 52W low
+75.1%
$2.81
$8.99
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Nutriband, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
33/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
84
Growth
73
Issuance
57
Momentum
38
Value
23
Revisions
20
Volatility
15
Quality
13

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (13): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NTRB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTRB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00$16.00Jan 26Apr 26Jul 26Oct 26NTRBHigh $15Median $15Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$15
Low
$15
Median
$15
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Jan 2025Noble Capital MarketsInitiatesOutperform$13
26 July 2022Small Cap Consumer ResearchMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NTRB.

Market Radar

This page is one stock. Monday covers all of them.

NTRB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NTRB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Nutriband, Inc. returned −2.4% against +6.9% for the S&P 500, dividends included.

NTRB vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26NTRBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NTRB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
37.2×

Cheaper than 5% of US stocks

Price / book
11.3×

Cheaper than 6% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−29.7%

Higher than 9% of US stocks

Earnings growth (YoY)
—
Gross margin
41.6%

Higher than 52% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−100.7%

Higher than 13% of US stocks

Return on assets
−53.5%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nutriband, Inc. has a market value of $60.8M and an enterprise value of $57.6M.

  • Revenue in the twelve months to 31 July 2026: $1.6M. The latest quarter shrank 29.7% year on year.

  • Net income over the same four quarters: −$7.0M, a −430.4% net margin.

  • Free cash flow in the twelve months to 31 July 2026: −$3.6M.

  • Shares outstanding: 12.2M.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

NTRB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NTRBNutriband, Inc.$60.8M33
CSBRChampions Oncology, Inc.$59.8M27
NMRANeumora Therapeutics, Inc.$60.8M35
VTVTvTv Therapeutics, Inc.$61.1M69
NRXSNeurAxis, Inc.$58.3M47
TENXTenax Therapeutics, Inc.$56.9M24
FBIOFortress Biotech, Inc.$63.1M87

Take a look at NTRB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Nutriband, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NTRB

What is the NTRB stock price forecast for 2026-2027?

The median 12-month analyst price target for Nutriband, Inc. is $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTRB stock a buy right now?

Of the 1 analyst covering Nutriband, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nutriband, Inc. 33 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTRB?

As at 21 Nov 2026, Nutriband, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will NTRB stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $15, and Ticker Nerd's factor model ranks Nutriband, Inc. 33 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTRB stock forecast for 2030?

No analyst covering Nutriband, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $15 over the next 12 months.

How has NTRB stock performed over the past year?

Nutriband, Inc. returned -2.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nutriband, Inc. do?

Nutriband Inc. is a pharmaceutical company focused on the development of transdermal drug delivery products. The company’s core work centers on abuse-deterrent patch technologies designed to reduce the risk of misuse, diversion, and accidental exposure for drugs with abuse potential, particularly opioids.

Company

About Nutriband, Inc.

Nutriband Inc. is a pharmaceutical company focused on the development of transdermal drug delivery products. The company’s core work centers on abuse-deterrent patch technologies designed to reduce the risk of misuse, diversion, and accidental exposure for drugs with abuse potential, particularly opioids. Its lead development program is AVERSA Fentanyl, alongside additional transdermal products such as AVERSA Buprenorphine and AVERSA Methylphenidate. Nutriband also operates through business segments that include pharmaceuticals and medical devices, supporting both product development and related manufacturing activities. Based in Orlando, Florida, Nutriband serves the healthcare market by advancing patch-based therapies that aim to deliver medications through the skin in a controlled and convenient format.

CEO Mr. Gareth Sheridan · United States · https://www.nutriband.com